Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ARRY Array BioPharma Inc. daily Stock Chart
ARRY [NASD]
Array BioPharma Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.53 Insider Own0.40% Shs Outstand207.93M Perf Week6.05%
Market Cap4.81B Forward P/E- EPS next Y-0.41 Insider Trans-57.01% Shs Float207.93M Perf Month37.51%
Income-111.50M PEG- EPS next Q-0.19 Inst Own99.00% Short Float9.88% Perf Quarter57.24%
Sales241.30M P/S19.93 EPS this Y-3.70% Inst Trans3.65% Short Ratio6.31 Perf Half Y68.46%
Book/sh1.32 P/B17.52 EPS next Y28.10% ROA-22.40% Target Price26.82 Perf Year34.87%
Cash/sh2.29 P/C10.08 EPS next 5Y10.00% ROE-45.10% 52W Range12.56 - 22.80 Perf YTD62.32%
Dividend- P/FCF- EPS past 5Y-5.30% ROI-41.80% 52W High1.47% Beta1.44
Dividend %- Quick Ratio6.30 Sales past 5Y20.10% Gross Margin85.50% 52W Low84.16% ATR0.93
Employees298 Current Ratio6.30 Sales Q/Q95.50% Oper. Margin-42.80% RSI (14)76.72 Volatility4.42% 4.60%
OptionableYes Debt/Eq0.46 EPS Q/Q69.10% Profit Margin-46.20% Rel Volume1.46 Prev Close22.04
ShortableYes LT Debt/Eq0.46 EarningsFeb 05 BMO Payout- Avg Volume3.26M Price23.13
Recom1.60 SMA2019.57% SMA5035.01% SMA20044.53% Volume4,741,637 Change4.95%
Jan-17-19Initiated Leerink Partners Outperform $28
Dec-13-18Initiated Goldman Neutral $20
Feb-07-18Reiterated Stifel Buy $20 → $23
Jan-22-18Upgrade Leerink Partners Mkt Perform → Outperform
Jan-22-18Reiterated Stifel Buy $15 → $20
Sep-11-17Reiterated Stifel Buy $13 → $15
May-03-17Upgrade JP Morgan Neutral → Overweight
Feb-03-17Reiterated Stifel Buy $8 → $13
Feb-03-17Downgrade JP Morgan Overweight → Neutral
Jan-30-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-26-16Reiterated Piper Jaffray Overweight $7 → $10
Sep-26-16Reiterated Leerink Partners Outperform $6 → $9
Jan-26-15Reiterated Stifel Buy $6 → $9
Aug-09-13Reiterated Stifel Buy $7 → $8
Jul-23-10Upgrade UBS Neutral → Buy $4.25
Apr-22-10Downgrade UBS Buy → Neutral
Nov-05-09Upgrade UBS Neutral → Buy
Sep-08-09Downgrade UBS Buy → Neutral
Sep-04-09Downgrade Robert W. Baird Outperform → Neutral $10 → $3
Sep-04-09Downgrade Leerink Swann Outperform → Mkt Perform $6 → $2
Feb-14-19 02:02PM  Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up Zacks
Feb-07-19 09:34PM  Edited Transcript of ARRY earnings conference call or presentation 5-Feb-19 2:00pm GMT Thomson Reuters StreetEvents
06:34AM  Will Array BioPharma Continue to Surge Higher? Zacks
Feb-06-19 08:40AM  Array BioPharma (ARRY) Soars: Stock Adds 11% in Session Zacks
08:23AM  The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
Feb-05-19 04:19PM  Array BioPharma Surges as Loss Is Narrower Than Expected TheStreet.com +10.96%
03:39PM  Here's What Sent Array BioPharma Soaring 11.3% Today Motley Fool
02:03PM  Array Biopharma Inc (ARRY) Q2 2019 Earnings Conference Call Transcript Motley Fool
01:14PM  Boulder biotech firm's skin cancer drugs drive 'strong' second quarter American City Business Journals
10:00AM  Here's Why Array BioPharma (ARRY) is a Great Momentum Stock to Buy Zacks
09:52AM  Array BioPharma (ARRY) Upgraded to Buy: Here's What You Should Know Zacks
09:15AM  Array BioPharma (ARRY) Reports Q2 Loss, Tops Revenue Estimates Zacks
08:12AM  Array BioPharma: Fiscal 2Q Earnings Snapshot Associated Press
08:00AM  Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019 PR Newswire
Feb-03-19 11:34AM  Here's Why Array BioPharma Jumped 31% in January Motley Fool
Jan-30-19 12:08PM  Does Array BioPharma Inc.s (NASDAQ:ARRY) CEO Pay Compare Well With Peers? Simply Wall St.
Jan-29-19 04:05PM  Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019 PR Newswire
10:31AM  Array BioPharma (ARRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
09:30AM  Has Array BioPharma (ARRY) Outpaced Other Medical Stocks This Year? Zacks
Jan-18-19 07:45AM  Moving Average Crossover Alert: Array BioPharma Zacks
Jan-17-19 10:00AM  What Makes Array BioPharma (ARRY) a Strong Momentum Stock: Buy Now? Zacks
Jan-15-19 04:48PM  Heres your guide to the upcoming biotechnology takeover wave MarketWatch
01:42PM  Analyst: This Biopharma Stock Could Surge 76% Schaeffer's Investment Research
07:55AM  Today's Research Reports on Trending Tickers: Array BioPharma and VIVUS ACCESSWIRE
Jan-14-19 05:02PM  Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer PR Newswire
Jan-09-19 08:25AM  Does Eli Lilly's $8 Billion Splurge Make Array BioPharma a Buy Now? Motley Fool
Jan-07-19 03:47PM  Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today Motley Fool +8.85%
Dec-21-18 10:22AM  Breakeven On The Horizon For Array BioPharma Inc. (NASDAQ:ARRY) Simply Wall St.
Dec-20-18 04:05PM  Array BioPharma to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-13-18 07:00AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Array BioPharma ACCESSWIRE
Dec-10-18 12:38AM  Is Array Biopharma Inc (ARRY) A Good Stock To Buy? Insider Monkey
Nov-20-18 04:05PM  Array BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-16-18 03:32PM  9 Colorado companies make Deloittes list of fastest-growing tech companies American City Business Journals
Nov-15-18 10:14AM  Array BioPharma Inc (NASDAQ:ARRY) Is Trading At A 48.17% Discount Simply Wall St. +8.12%
Nov-07-18 05:15AM  Edited Transcript of ARRY earnings conference call or presentation 30-Oct-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-06-18 04:05PM  Array BioPharma to Present at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference PR Newswire
Nov-02-18 07:50AM  Analysis: Positioning to Benefit within Array BioPharma, SPX FLOW, Holly Energy Partners, Electro Scientific Industries, Leggett & Platt, and CBL & Associates Properties Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-01-18 02:46PM  Harry Boxers four stocks to watch this week MarketWatch
Oct-31-18 03:31PM  Why Array BioPharma Is Soaring Today Motley Fool +7.71%
Oct-30-18 09:25AM  Array BioPharma (ARRY) Reports Q1 Loss, Tops Revenue Estimates Zacks
08:20AM  Array BioPharma: Fiscal 1Q Earnings Snapshot Associated Press
08:00AM  Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019 PR Newswire
Oct-26-18 08:00AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Array BioPharma ACCESSWIRE
Oct-23-18 04:05PM  Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2019 on October 30, 2018 PR Newswire
10:32AM  Array BioPharma (ARRY) Q1 Earnings Preview: What to Watch Ahead of the Release Zacks
Sep-27-18 02:19PM  Is Array BioPharma Incs (NASDAQ:ARRY) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Sep-26-18 08:00AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Array BioPharma ACCESSWIRE
Sep-25-18 04:05PM  Array BioPharma to Present at the 2018 Cantor Global Healthcare Conference PR Newswire
Sep-20-18 02:02PM  European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for Advanced BRAF-mutant Melanoma PR Newswire
Sep-13-18 08:00AM  Array BioPharma Announces Publication of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) Phase 3 Overall Survival Data in The Lancet Oncology PR Newswire
Aug-31-18 03:56PM  Edited Transcript of ARRY earnings conference call or presentation 14-Aug-18 1:00pm GMT Thomson Reuters StreetEvents
08:30AM  Research Report Identifies Engility, SLM, Kraton, AAC, Array BioPharma, and Symantec with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-30-18 04:05PM  Array BioPharma to Present at the Wells Fargo Securities 2018 Healthcare Conference PR Newswire
Aug-29-18 08:00AM  Today's Research Reports on Trending Tickers: Aerie Pharmaceuticals, Inc. and Array BioPharma Inc. ACCESSWIRE
Aug-22-18 08:00AM  Today's Research Reports on Trending Tickers: Array BioPharma and Intercept Pharmaceuticals ACCESSWIRE
Aug-17-18 08:00AM  Today's Research Reports on Trending Tickers: Array BioPharma and AVEO Pharmaceuticals ACCESSWIRE
Aug-14-18 01:28PM  Array BioPharma Inc. (ARRY) Q4 2018 Earnings Conference Call Transcript Motley Fool
09:30AM  Array BioPharma (ARRY) Reports Q4 Loss, Misses Revenue Estimates Zacks
08:33AM  Array BioPharma: Fiscal 4Q Earnings Snapshot Associated Press
08:00AM  Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 PR Newswire
07:00AM  Array BioPharma Inc. to Host Earnings Call ACCESSWIRE
Aug-10-18 08:00AM  Array BioPharma Names Carrie S. Cox Chairman of its Board of Directors PR Newswire
Aug-07-18 04:05PM  Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 on August 14, 2018 PR Newswire
08:00AM  Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer PR Newswire
Jul-27-18 08:30AM  BRAFTOVI (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma PR Newswire -7.71%
07:40AM  Market Trends Toward New Normal in Egalet, PPG Industries, Synergy Pharmaceuticals, Equity Residential, Array BioPharma, and Holly Energy Partners Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jul-18-18 08:08AM  Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates Zacks
Jul-17-18 07:10AM  Wired News - NCCN Recommends BRAFTOVI with MEKTOVI as Category 1 Treatment Option for BRAF-Mutant Melanoma ACCESSWIRE
Jul-13-18 08:00AM  The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI (encorafenib) in Combination with MEKTOVI® (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma PR Newswire
Jun-28-18 11:42AM  Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking Benzinga
08:00AM  Today's Research Reports on Trending Tickers: Heron Therapeutics and Array BioPharma ACCESSWIRE
Jun-27-18 02:58PM  Array BioPharma gets FDA nod for melanoma combo treatment Reuters
02:19PM  Array BioPharma Touts Approval Of Melanoma Drug Benzinga
01:44PM  Array BioPharma Announces FDA Approval of BRAFTOVI (encorafenib) in Combination with MEKTOVI® (binimetinib) PR Newswire
01:40PM  UPDATE 1-FDA approves Array BioPharma's melanoma combo treatment Reuters
01:05PM  Array's melanoma combo treatment wins FDA approval Reuters
Jun-26-18 07:10AM  Free Technical Reports on Array BioPharma and Three Additional Biotech Equities ACCESSWIRE
Jun-23-18 07:00AM  Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Cancer PR Newswire
Jun-21-18 08:49AM  Array BioPharma (ARRY) Looks Good: Stock Adds 5.2% in Session Zacks
Jun-20-18 03:55PM  Harry Boxer: Marijuana companies Aurora Cannabis and Canopy Growth are breaking out MarketWatch +5.21%
08:00AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Array BioPharma ACCESSWIRE
Jun-18-18 08:00AM  Array BioPharma to Present Overall Survival Results from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the ESMO 20th World Congress on Gastrointestinal Cancer PR Newswire
Jun-17-18 04:16PM  The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs Benzinga
Jun-05-18 09:37AM  Are New Drug Approvals Right Around the Corner for Trevena (TRVN) and Array Biopharma (ARRY)? SmarterAnalyst +5.09%
Jun-04-18 10:10AM  What does Array BioPharma Incs (NASDAQ:ARRY) Balance Sheet Tell Us About Its Future? Simply Wall St.
08:00AM  Array BioPharma Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with BRAF-mutant Advanced Melanoma PR Newswire
Jun-01-18 03:56PM  Key FDA Events in June Investors Need to Watch Out For Zacks
May-31-18 09:32AM  George Soros Bought This Clinical-Stage Biotech Stock. Should You? Motley Fool
06:31AM  3 Biotechs With Huge FDA Decisions in June Motley Fool
May-30-18 04:05PM  Array BioPharma To Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
May-18-18 04:12AM  Edited Transcript of ARRY earnings conference call or presentation 9-May-18 1:00pm GMT Thomson Reuters StreetEvents
May-16-18 05:17PM  Array BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination of Encorafenib and Binimetinib in Patients with BRAF-mutant Melanoma at 2018 ASCO Annual Meeting PR Newswire
07:05AM  Free Stock Performance Review on Array BioPharma and Three More Biotech Industry ACCESSWIRE
May-15-18 07:00AM  Wired News Kitov Pharma Signs Consensi(TM) Commercialization Deal with Changshan Pharma in China ACCESSWIRE
May-11-18 08:39AM  Array BioPharma (ARRY) in Focus: Stock Moves 5.5% Higher Zacks
03:40AM  Will Array Biopharma Break Its Downtrend? Investopedia
May-09-18 04:05PM  Array Biopharma To Present At The Bank Of America Merrill Lynch 2018 Health Care Conference PR Newswire
11:39AM  Array BioPharma Inc (NASDAQ:ARRY): Should The Recent Earnings Drop Worry You? Simply Wall St.
08:14AM  Array BioPharma: Fiscal 3Q Earnings Snapshot Associated Press
08:00AM  Array BioPharma Reports Financial Results For The Third Quarter of Fiscal 2018 PR Newswire
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. The company's lead clinical programs include encorafenib and binimetinib that are investigated in approximately 30 clinical trials for various solid tumor indications, including a Phase III trial in BRAF-mutant colorectal cancer. Its product pipeline also includes ipatasertib, an AKT inhibitor that is in Phase III trial to treat prostate or breast cancers; selumetinib, a MEK inhibitor for cancer; larotrectinib, a PanTrk inhibitor that is in a Phase II/registration clinical trial for cancer; tucatinib, a HER2 inhibitor for breast cancer, which is in Phase II/registration trial; and ARRY-797 that is in Phase III clinical trial for Lamin A/C-related dilated cardiomyopathy. In addition, the company is developing varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric cancer; ARRY-382, a CSF1R inhibitor that is in Phase II clinical trial to treat cancer; motolimod/VTX-2337, a Toll-like receptor that is in Phase II clinical trial for cancer; and prexasertib/LY2606368, a CHK-1 inhibitor, which is in multiple Phase I or II clinical trials for cancer. Further, its drug candidates in Phase I clinical trials include GDC-0575, a CHK-1 inhibitor for cancer; LOXO-292, a RET inhibitor to treat cancer; and LOXO-195, a Trk inhibitor for cancer. Additionally, its drug candidates include Ganovo/danoprevir, a protease inhibitor for hepatitis C virus. The company was founded in 1998 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Squarer RonCEOFeb 07Option Exercise3.61110,000397,100348,709Feb 08 06:31 PM
Saccomano Nicholas ACSOFeb 07Option Exercise3.67187,264687,509329,752Feb 08 06:32 PM
Haddock JasonCFOFeb 07Option Exercise3.7785,000320,450115,059Feb 08 06:34 PM
Saccomano Nicholas ACSOFeb 07Sale21.58187,2644,041,756142,488Feb 08 06:32 PM
Haddock JasonCFOFeb 07Sale22.0585,0001,874,30130,059Feb 08 06:34 PM
Squarer RonCEOFeb 07Sale21.64110,0002,380,015238,709Feb 08 06:31 PM
Robbins Andrew RCOOFeb 06Option Exercise5.70125,000712,625299,620Feb 08 06:36 PM
LEFKOFF KYLEDirectorFeb 06Option Exercise10.4725,000261,75047,720Feb 08 07:14 PM
LEFKOFF KYLEDirectorFeb 06Sale20.8410,000208,38220,000Feb 08 07:14 PM
LEFKOFF KYLEDirectorFeb 06Sale20.5125,000512,69322,720Feb 08 07:14 PM
Robbins Andrew RCOOFeb 06Sale20.03239,6264,798,51159,994Feb 08 06:36 PM
Haddock JasonCFOFeb 06Sale20.0011,712234,24030,059Feb 08 06:34 PM
Oltmans Curtis GaleGeneral CounselFeb 05Option Exercise8.9440,000357,60055,021Feb 07 04:30 PM
Oltmans Curtis GaleGeneral CounselFeb 05Sale20.0040,000800,00015,021Feb 07 04:30 PM
Squarer RonCEOJan 31Option Exercise7.30113,438828,097352,147Feb 01 08:44 PM
Squarer RonCEOJan 31Sale18.53113,4382,101,541238,709Feb 01 08:44 PM
Squarer RonCEOJan 30Option Exercise3.61100,000361,000338,709Feb 01 08:44 PM
Squarer RonCEOJan 30Sale18.25100,0001,825,370238,709Feb 01 08:44 PM
Oltmans Curtis GaleGeneral CounselJan 29Option Exercise8.9411,10099,23415,021Feb 07 04:30 PM
Oltmans Curtis GaleGeneral CounselJan 25Option Exercise8.9414,029125,41917,950Jan 29 04:27 PM
Oltmans Curtis GaleGeneral CounselJan 25Sale18.0014,029252,5233,921Jan 29 04:27 PM
Oltmans Curtis GaleGeneral CounselJan 18Option Exercise8.941,25111,1845,172Jan 23 04:47 PM
Oltmans Curtis GaleGeneral CounselJan 18Sale18.001,25122,5183,921Jan 23 04:47 PM
Oltmans Curtis GaleGeneral CounselJan 15Option Exercise8.9419,720176,29723,641Jan 17 04:58 PM
Oltmans Curtis GaleGeneral CounselJan 15Sale18.0619,720356,1393,921Jan 17 04:58 PM
Sandor VictorChief Medical OfficerDec 27Sale14.056,26888,091228,998Jan 02 04:32 PM
Robbins Andrew RCOODec 16Option Exercise0.0027,0510186,518Dec 18 07:48 PM
Saccomano Nicholas ACSODec 16Option Exercise0.0012,469074,162Dec 18 07:49 PM
Sandor VictorChief Medical OfficerDec 16Option Exercise0.0023,3460245,644Dec 18 07:49 PM
Haddock JasonCFODec 16Option Exercise0.0011,387046,780Dec 18 07:48 PM
Squarer RonCEODec 16Option Exercise0.0048,4370260,012Dec 18 07:48 PM
Oltmans Curtis GaleGeneral CounselDec 16Option Exercise0.007,00007,000Dec 18 07:48 PM
Sandor VictorChief Medical OfficerDec 03Option Exercise3.65127,397464,999337,483Dec 06 04:02 PM
Sandor VictorChief Medical OfficerDec 03Sale16.21115,1851,867,045222,298Dec 06 04:02 PM
COX CARRIE SMITHDirectorNov 01Buy16.873,00050,5953,000Nov 05 04:37 PM
VAN LUNSEN GIL JDirectorSep 19Option Exercise5.9518,000107,10037,297Sep 21 04:18 PM
VAN LUNSEN GIL JDirectorSep 19Sale14.7618,000265,68419,297Sep 21 04:18 PM
Sandor VictorChief Medical OfficerSep 04Sale15.389,687148,938210,086Sep 05 04:18 PM
VAN LUNSEN GIL JDirectorAug 15Option Exercise5.7121,500122,85040,797Aug 17 04:46 PM
VAN LUNSEN GIL JDirectorAug 15Sale13.9221,500299,28019,297Aug 17 04:46 PM
Haddock JasonCFOAug 15Sale13.9220,000278,40035,393Aug 17 04:46 PM
Haddock JasonCFOJul 30Option Exercise3.7751,525194,24980,393Jul 31 04:57 PM
Haddock JasonCFOJul 30Sale14.8725,000371,75055,393Jul 31 04:57 PM
VAN LUNSEN GIL JDirectorJul 18Option Exercise5.3621,500115,23040,797Jul 19 04:26 PM
VAN LUNSEN GIL JDirectorJul 18Sale16.5621,500356,04019,297Jul 19 04:26 PM
LEFKOFF KYLEDirectorJul 06Option Exercise5.5450,000277,00067,720Jul 06 04:06 PM
LEFKOFF KYLEDirectorJul 06Sale17.4550,000872,50017,720Jul 06 04:06 PM
Robbins Andrew RCOOJun 27Option Exercise0.0032,0680191,535Jun 29 04:22 PM
Saccomano Nicholas ACSOJun 27Option Exercise0.0011,453066,731Jun 29 04:22 PM
Sandor VictorChief Medical OfficerJun 27Option Exercise0.0017,4400227,526Jun 29 04:21 PM
Squarer RonCEOJun 27Option Exercise5.66218,5061,236,094352,200Jun 29 04:22 PM
Squarer RonCEOJun 27Sale17.96184,2533,309,429211,575Jun 29 04:22 PM
Robbins Andrew RCOOJun 27Sale17.7417,964318,681159,467Jun 29 04:22 PM
VAN LUNSEN GIL JDirectorJun 20Option Exercise4.8621,500104,52040,797Jun 21 04:20 PM
VAN LUNSEN GIL JDirectorJun 20Sale19.0821,500410,22019,297Jun 21 04:20 PM
Sandor VictorChief Medical OfficerJun 19Option Exercise3.6577,576283,152287,662Jun 21 04:20 PM
Sandor VictorChief Medical OfficerJun 19Sale18.7677,5761,455,326210,086Jun 21 04:20 PM
Sandor VictorChief Medical OfficerJun 13Option Exercise3.6522,42481,848232,510Jun 15 04:25 PM
Sandor VictorChief Medical OfficerJun 13Sale18.7522,424420,450210,086Jun 15 04:25 PM
VAN LUNSEN GIL JDirectorMay 16Option Exercise4.1521,50089,33040,797May 17 04:01 PM
VAN LUNSEN GIL JDirectorMay 16Sale15.3621,500330,25919,297May 17 04:01 PM
VAN LUNSEN GIL JDirectorApr 18Option Exercise3.7821,50081,22540,797Apr 18 04:38 PM
VAN LUNSEN GIL JDirectorApr 18Sale15.1921,500326,58519,297Apr 18 04:38 PM
Sandor VictorChief Medical OfficerApr 03Sale15.358,689133,376210,086Apr 03 06:49 PM
Sandor VictorChief Medical OfficerApr 01Option Exercise0.007,8120225,711Apr 03 06:49 PM
Robbins Andrew RCOOApr 01Option Exercise0.009,8440168,142Apr 03 06:48 PM
Squarer RonCEOApr 01Option Exercise0.0018,9060228,180Apr 03 06:48 PM
Saccomano Nicholas ACSOApr 01Option Exercise0.006,875061,396Apr 03 06:48 PM
VAN LUNSEN GIL JDirectorMar 21Option Exercise3.4621,50074,48540,797Mar 21 05:11 PM
VAN LUNSEN GIL JDirectorMar 21Sale16.7621,500360,34019,297Mar 21 05:11 PM
Sandor VictorChief Medical OfficerMar 09Option Exercise3.65182,191664,997373,915Mar 09 05:42 PM
Sandor VictorChief Medical OfficerMar 09Sale17.71156,0162,763,714217,899Mar 09 05:42 PM
VAN LUNSEN GIL JDirectorFeb 21Option Exercise2.8021,50060,17040,797Feb 23 04:35 PM
VAN LUNSEN GIL JDirectorFeb 21Sale17.1621,500368,94019,297Feb 23 04:35 PM
open in yahoo | open in reuters | open in google